AOCC 2020 Virtual & Onsite

S01. AOCC Education Workshop: Tips from an expert

Room 3, December 16 (Wed), 09:00-10:30

Chairs Geun Am Song, Pusan National University, Korea
Tadakazu Hisamatsu, Kyorin University, Japan

09:00-09:20	Diagnosis of IBD: Clinical perspective Ida Hilmi, University of Malaya, Malaysia
09:20-09:40	Differential diagnosis of IBD: A pathologist's advice Jihun Kim, University of Ulsan, Korea
09:40-10:00	Role of conventional medications in the biologic era Yue Li, Peking Union Medical College Hospital, China
10:00-10:20	Optimization of IBD therapeutics by evolving treatment goals Miguel Regueiro, Cleveland Clinic, USA
10:20-10:30	Discussion

SS01. Treat to Target – A key piece of the IBD treatment puzzle

Room 1, December 16 (Wed), 09:30-10:30

Chairs Joo Sung Kim, Seoul National University, Korea
Kaichun Wu, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, China

09:30-10:00	Targeting success – A tight disease control strategy in IBD Edward V. Loftus, Jr., Mayo Clinic, USA
10:00-10:30	Evidence to support optimal IBD management in clinical practice Taku Kobayashi, Kitasato University Kitasato Institute Hospital, Japan

SS02. Personalized CD management: Are we there yet?

Room 2, December 16 (Wed), 09:30-10:30

Chairs Hwang Choi, The Catholic University of Korea, Korea
Zhihua Ran, Shanghai Jiao-Tong University School of Medicine, China

09:30-10:00	Treat-to-target as a management strategy in CD Siew Chien Ng, The Chinese University of Hong Kong, Hong Kong
10:00-10:30	How to choose and sequence CD treatment in bio-naïve patients? Won Moon, Kosin University, Korea

S02. Current issues of IBD in Asia

Room 1, December 16 (Wed), 10:50-12:20

Chairs Won Ho Kim, Yonsei University, Korea
Kaichun Wu, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, China

10:50-11:10	Epidemiological trends of IBD: What is new? Siew Chien Ng, The Chinese University of Hong Kong, Hong Kong
11:10-11:30	Diagnostic challenges of IBD: How to differentiate IBD mimics? Zhihua Ran, Shanghai Jiao-Tong University School of Medicine, China
11:30-11:50	Smart use of thiopurine and anti-TNF: What should we know? Tadakazu Hisamatsu, Kyorin University, Japan
11:50-12:05	Early course of newly diagnosed moderate-to-severe ulcerative colitis in Korea: A population-based inception cohort study (MOSAIK) Jin Young Yoon, Kyung Hee University, Korea
12:05-12:20	Thiopurine combination therapy ≥6 months significantly increases biological agent persistence in inflammatory bowel disease: Real-world prospective population data Yanna Ko, Concord Repatriation General Hospital, Australia

S03. New frontiers in the pathogenesis of IBD

Room 2, December 16 (Wed), 10:50-12:20

Chairs Mi-Na Kweon, University of Ulsan, Korea
Tae Il Kim, Yonsei University, Korea

10:50-11:10	Recent updates on genetics research and its clinical implications Dermot P.B. McGovern, Cedars-Sinai Medical Center, USA
11:10-11:30	Crosstalk between microbiome and host immune system Mi-Na Kweon, University of Ulsan, Korea
11:30-11:50	Mucosal immune response and novel therapeutic targets Jae Hee Cheon, Yonsei University, Korea
11:50-12:10	Cellular and molecular mechanisms of intestinal fibrosis Ren Mao, The First Affiliated Hospital of Sun Yat-sen University, China
12:10-12:20	Discussion

S04. Up-to-date radiological imaging in IBD

Room 3, December 16 (Wed), 10:50-12:20

Chairs Pin-Jin Hu, The Sixth Affiliated Hospital, Sun Yat-sen University, China
Se Hyung Kim, Seoul National University, Korea

10:50-11:10	Update on the role of CT enterography Se Hyung Kim, Seoul National University, Korea
11:10-11:30	Current status and future directions of MR Enterography Seong Ho Park, University of Ulsan, Korea
11:30-11:50	Ultrasonography as an emerging tool for IBD Jiro Hata, Kawasaki Medical School, Japan
11:50-12:05	Preoperative multiparameter magnetic resonance enterography for prediction of early anastomotic recurrence after primary ileocolic resection in patients with Crohn's disease Jinfang Du, The First Affiliated Hospital, Sun Yat-sen University, China
12:05-12:20	Is mixed use of MR enterography and CT enterography adequate for routine periodic follow-up for bowel inflammation in patients with Crohn's disease? Jiyeon Ha, Asan Medical Center, Korea

SS03. How to sequence advanced therapies in IBD

Room 1, December 16 (Wed), 12:20-13:20

Chairs Yoon Tae Jeen, Korea University, Korea
Haruhiko Ogata, Keio University, Japan

12:20-12:50	Why sequencing matters? Katsuyoshi Matsuoka, Toho University Sakura Medical Center, Japan
12:50-13:20	Which therapy and when? Brian L Bressler, University of British Columbia, Canada

SS04. Past, present and future of infliximab

Room 3, December 16 (Wed), 12:20-13:20

Chairs Won Ho Kim, Yonsei University, Korea
Yu-Fang Wang, West China Hospital, Sichuan University, China

12:20-12:50	Treatment optimization with therapeutic drug monitoring Geom Seog Seo, Wonkwang University, Korea
12:50-13:20	Future of infliximab: Subcutaneous formulation Byong Duk Ye, University of Ulsan, Korea

S05. Microbiome in IBD: Friends or foes?

Room 1, December 16 (Wed), 13:40-15:10

Chairs Dong Soo Han, Hanyang University, Korea
Zheng Qing, Renji Hospital, China

13:40-14:00	Good bugs and bad bugs in colitis and colitis-associated cancer Christian Jobin, University of Florida, USA
14:00-14:20	Viruses and fungi in the pathogenic and therapeutic perspectives Takayuki Imai, Shiga University of Medical Science, Japan
14:20-14:40	FMT: Where are we now and where are we going? Young-Seok Cho, The Catholic University of Korea, Korea
14:40-15:00	The future of microbiome engineering for IBD treatment Harry Sokol, Saint-Antoine Hospital, France
15:00-15:10	Discussion

S06. Recent advances in diagnosis and monitoring of IBD

Room 2, December 16 (Wed), 13:40-15:10

Chairs Hyo Jong Kim, Kyung Hee University, Korea
Akira Andoh, Shiga University of Medical Science, Japan

13:40-14:00	Optimal diagnosis in IBD: What will it change? Silvio Danese, Humanitas Research Hospital, Italy
14:00-14:20	Emerging roles of biomarkers in IBD Shiro Nakamura, 2nd Department of Internal Medicine, Osaka Medical College, Japan
14:20-14:40	Therapeutic drug monitoring: How, when, and for whom? Jia-Feng Wu, National Taiwan University Hospital, Taiwan
14:40-14:55	Pharmacokinetics and immune mechanisms in patients receiving dose-optimization for loss-of-response to vedolizumab Bella Ungar, Chaim Sheba Medical Center, Israel
14:55-15:10	Degree of creeping fat assessed by CT enterography is associated with intestinal fibrotic stricture in patients with crohns disease: A potentially novel mesenteric fat creeping index Xuehua Li, The First Affiliated Hospital of Sun Yat-Sen University, China

S07. Looking into the operating room of IBD surgeons

Room 3, December 16 (Wed), 13:40-15:10

Chairs Kyu Joo Park, Seoul National University, Korea
Kil Yeon Lee, Kyung Hee University, Korea

13:40-14:00	Evolving role of IBD surgery Willem A. Bemelman, Amsterdam University Medical Centers, Netherlands
14:00-14:20	Total proctocolectomy in UC: Tips for laparoscopic surgery Seung-Bum Ryoo, Seoul National University, Korea
14:20-14:40	Perianal Crohn’s disease: Surgical options to save anus Keisuke Hata, Nihonbashi-Muromachi Mitsui Tower Midtown Clinic, Japan
14:40-15:00	Experiences of IBD Surgery in the era of biologics Kil Yeon Lee, Kyung Hee University, Korea
15:00-15:10	Discussion

S08. ECCO-AOCC Forum 2020

Room 1, December 16 (Wed), 15:30-17:00

Chairs Laurent Peyrin-Biroulet, Nancy University Hospital, France
Yoon Tae Jeen, Korea University, Korea

15:30-15:45	Part 1. Small bowel CD Identification of stricture characteristic using cross sectional images: inflammatory vs fibrotic Se Hyung Kim, Seoul National University, Korea
15:45-16:00	Part 1. Small bowel CD Nonsurgical therapies: drugs and balloon Takayuki Matsumoto, Iwate Medical University, Japan
16:00-16:15	Part 1. Small bowel CD Surgical treatment: optimal timing, preparation, and technique Willem A. Bemelman, Amsterdam University Medical Centers, Netherlands
16:15-16:30	Part 2. Acute severe UC Optimal strategies for drug therapy: Which one, when, and how? Hiroshi Nakase, Sapporo Medical University, Japan
16:30-16:45	Part 2. Acute severe UC Review of outcome predictors: prognosticators and available indices Silvio Danese, Humanitas Research Hospital, Italy
16:45-17:00	Part 2. Acute severe UC State of the art for surgical treatment Kyu Joo Park, Seoul National University, Korea

S09. Multidisciplinary approach in challenging cases

Room 2, December 16 (Wed), 15:30-17:00

Chairs Kyung Mo Kim, University of Ulsan, Korea
Young Sook Park, Eulji University, Korea

	Panel Seong Ho Park, University of Ulsan, Korea Yong Sik Yoon, University of Ulsan, Korea Yeoun Joo Lee, Pusan National University, Korea Su Young Kim, Yonsei University Wonju, Korea
15:30-16:00	Surgeon’s perspective for complicated CD Yong Sik Yoon, University of Ulsan, Korea
16:00-16:30	Growth in pediatric Crohn's disease Yeoun Joo Lee, Pusan National University, Korea
16:30-17:00	Optimal management for colitis-associated rectal cancer Su Young Kim, Yonsei University Wonju, Korea

SS05. Evolving therapeutic goals in ulcerative colitis: Important role of 5-ASA

Room 3, December 16 (Wed), 15:30-16:00

Chairs David Ong Eng Hui, National University Hospital Singapore, Singapore
Dong Kyung Chang, Sungkyunkwan University, Korea

15:30-15:45	Evolving therapeutic goals in ulcerative colitis: Important role of 5-ASA Silvio Danese, Humanitas Research Hospital, Italy
15:45-16:00	Patient' survey of PENTASA® Sachet 2g in Korea: In patient's perspective of adherence and compliance Won Moon, Kosin University, Korea

Scientific Program